<DOC>
	<DOCNO>NCT01203202</DOCNO>
	<brief_summary>The purpose study evaluate whether PED-1 ( 15mg ) PED-2 ( 30mg ) tolerable effective treatment premature ejaculation .</brief_summary>
	<brief_title>Phase 2 Trial PED-1 PED-2 Male Patients With Premature Ejaculation</brief_title>
	<detailed_description>This study evaluate whether PED-1 PED2 tolerable effective treatment premature ejaculation . The patient randomize allocated three treatment group placebo , PED-1 , PED-2 . The creteria IELT enrollment &gt; =2 min least 75 % sexual intercourse . To diagnosis premature ejaculation , PEDT use . The patient ungone drug free baseline line period take test drug 4 week .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<mesh_term>Clomipramine</mesh_term>
	<criteria>Informed consent subject partdners Men 2065 stable monogamous relation least 6 mn PEDT 9 least 6 Mn premature ejaculation Hx IELT = &lt; 2 min &gt; = 75 % evaluable event 4 week secreening period Hx medical psychiartric illness erectile dysfunction ( &lt; 21 IIEF EF domain score ) form sexual dysfunction Partner sexual dysfunction know hypersensitivity clomipramine contraindication clomipramine</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PE</keyword>
	<keyword>IELT</keyword>
	<keyword>DCIT</keyword>
</DOC>